Aclaris Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
Rhea-AI Summary
Aclaris Therapeutics (NASDAQ: ACRS) reported its Q2 2024 financial results and provided a corporate update. Key highlights include:
1. Initiation of Phase 2a study activities for ATI-2138 in atopic dermatitis.
2. Strengthened balance sheet through sale of future OLUMIANT® royalties for up to $31.5 million.
3. Q2 2024 net loss of $11.0 million, compared to $29.6 million in Q2 2023.
4. Total revenue increased to $2.8 million in Q2 2024 from $1.9 million in Q2 2023.
5. R&D expenses decreased to $8.8 million from $25.3 million year-over-year.
6. Cash, cash equivalents, and marketable securities of $149.9 million as of June 30, 2024.
The company expects its current cash position, including the $26.5 million from the OLUMIANT® royalty sale, to fund operations into 2028.
Positive
- Initiated Phase 2a study for ATI-2138 in atopic dermatitis
- Strengthened balance sheet with up to $31.5 million from OLUMIANT® royalty sale
- Total revenue increased by 47% year-over-year to $2.8 million in Q2 2024
- R&D expenses decreased by 65% to $8.8 million in Q2 2024
- Cash runway extended into 2028
Negative
- Net loss of $11.0 million in Q2 2024
- Cash position decreased from $181.9 million at end of 2023 to $149.9 million as of June 30, 2024
News Market Reaction – ACRS
In the trading session that priced this news, ACRS declined 2.46%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
-Initiated Phase 2a Study Activities for ATI-2138 in Atopic Dermatitis-
-Strengthened Balance Sheet Through Sale of Future OLUMIANT® Royalties for Proceeds of up to
WAYNE, Pa., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the second quarter of 2024 and provided a corporate update.
"With study activities underway for our ATI-2138 Phase 2a trial in moderate to severe atopic dermatitis and the strengthening of our balance sheet through the completion of our royalty purchase agreement with OMERS, we're well-positioned to drive our strategic initiatives forward,” said Dr. Neal Walker, Interim President & CEO and Chair of the Board of Directors of Aclaris. “Our focus remains on leveraging our resources to maximize the potential of our innovative drug candidates, pursue available opportunities, and create long-term value for patients and shareholders alike."
Research and Development Highlights:
- ITK Inhibitor Programs
- ATI-2138, an investigational oral covalent ITK/JAK3 inhibitor
- ATI-2138-AD-201: Aclaris is activating clinical sites and expects to enroll patients in the coming weeks in this Phase 2a open-label trial to investigate the safety, tolerability, pharmacokinetics, efficacy, and pharmacodynamics of ATI-2138 in subjects with moderate to severe atopic dermatitis (AD).
- ITK Selective Compound
- Aclaris is progressing to development candidate selection a second generation ITK selective inhibitor for autoimmune indications.
- ATI-2138, an investigational oral covalent ITK/JAK3 inhibitor
- Lepzacitinib (ATI-1777), an investigational topical “soft” JAK 1/3 inhibitor
- In January 2024, Aclaris reported positive top-line results from its Phase 2b trial of lepzacitinib in atopic dermatitis (AD).
- Aclaris is currently seeking a global development and commercialization partner for this program (excluding Greater China). As previously announced, in 2022 Aclaris granted Pediatrix Therapeutics exclusive rights to develop and commercialize lepzacitinib in Greater China.
- Zunsemetinib (ATI-450), an investigational oral small molecule MK2 inhibitor
- Aclaris plans to support Washington University in St. Louis in its investigator-initiated Phase 1b/2 trials of zunsemetinib as a potential treatment for pancreatic cancer and metastatic breast cancer. Aclaris expects these trials to be primarily funded by grants awarded to Washington University.
Financial Highlights:
Liquidity and Capital Resources
As of June 30, 2024, Aclaris had aggregate cash, cash equivalents and marketable securities of
Aclaris anticipates that its cash, cash equivalents and marketable securities as of June 30, 2024 in combination with the
Financial Results
Second Quarter 2024
- Net loss was
$11.0 million for the second quarter of 2024 compared to$29.6 million for the second quarter of 2023.
- Total revenue was
$2.8 million for the second quarter of 2024 compared to$1.9 million for the second quarter of 2023. The increase was primarily driven by an increase in royalties under the Lilly license agreement during the three months ended June 30, 2024.
- Research and development (R&D) expenses were
$8.8 million for the quarter ended June 30, 2024 compared to$25.3 million for the prior year period.
- The
$16.5 million decrease was primarily the result of lower:- Zunsemetinib development expenses associated with clinical activities for a Phase 2a trial for hidradenitis suppurativa which was completed in March 2023, a Phase 2b trial for rheumatoid arthritis which was completed in November 2023, a Phase 2b trial for psoriatic arthritis which was discontinued in December 2023, and drug candidate manufacturing costs;
- Costs associated with lepzacitinib preclinical development activities and a Phase 2b clinical trial for AD which was completed in January 2024;
- ATI-2138 development expenses, including costs associated with a Phase 1 MAD trial which was completed in September 2023 and other preclinical activities; and
- Compensation-related expenses due to a decrease in headcount and higher forfeiture credits.
- The
- General and administrative (G&A) expenses were
$4.8 million for the quarter ended June 30, 2024 compared to$8.3 million for the prior year period. The decrease was primarily due to a reduction in compensation-related expenses due to lower headcount and higher forfeiture credits, along with the recognition of bad debt expense recorded in the prior year period from Aclaris’ determination that collection of amounts due from EPI Health are uncertain as a result of their filing for Chapter 11 bankruptcy protection.
- Licensing expenses were
$1.3 million for the quarter ended June 30, 2024 compared to$0.6 million for the prior year period. The increase was due to an increase in royalties earned under the Lilly license agreement.
- Revaluation of contingent consideration resulted in a
$0.2 million loss for the quarter ended June 30, 2024 compared to a gain of$1.5 million for the prior year period.
Year-to-date 2024
- Net loss was
$27.9 million for the six months ended June 30, 2024 compared to$57.7 million for the six months ended June 30, 2023.
- Total revenue was
$5.2 million for the six months ended June 30, 2024 compared to$4.4 million for the six months ended June 30, 2023. The increase was primarily driven by an increase in royalties under the Lilly license agreement during the six months ended June 30, 2024.
- R&D expenses were
$18.6 million for the six months ended June 30, 2024 compared to$47.9 million for the prior year period.
- The
$29.3 million decrease was primarily the result of lower:- Zunsemetinib development expenses associated with clinical activities for a Phase 2a trial for hidradenitis suppurativa which was completed in March 2023, a Phase 2b trial for rheumatoid arthritis which was completed in November 2023, a Phase 2b trial for psoriatic arthritis which was discontinued in December 2023, and drug candidate manufacturing costs;
- Costs associated with lepzacitinib preclinical development activities and a Phase 2b clinical trial for AD which was completed in January 2024;
- ATI-2138 development expenses, including costs associated with a Phase 1 MAD trial which was completed in September 2023 and other preclinical activities; and
- Compensation-related expenses due to a decrease in headcount and higher forfeiture credits.
- The
- G&A expenses were
$11.6 million for the six months ended June 30, 2024 compared to$17.1 million for the prior year period. The decrease was primarily due to a reduction in compensation-related expenses due to lower headcount and higher forfeiture credits, a decrease in patent, legal and accounting related expenses, and the recognition of bad debt expense recorded in the prior year period from Aclaris’ determination that collection of amounts due from EPI Health are uncertain as a result of their filing for Chapter 11 bankruptcy protection.
- Licensing expenses were
$2.3 million for the six months ended June 30, 2024 compared to$1.6 million for the prior year period. The increase was due to an increase in royalties earned under the Lilly license agreement.
- Revaluation of contingent consideration resulted in a
$3.0 million loss for the six months ended June 30, 2024 compared to a gain of$2.3 million for the prior year period.
OLUMIANT® is a registered trademark of Eli Lilly and Company.
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of drug candidates powered by a robust R&D engine exploring protein kinase regulation. For additional information, please visit www.aclaristx.com.
Cautionary Note Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “anticipate,” “believe,” “expect,” “intend,” “may,” “plan,” “potential,” “will,” and similar expressions, and are based on Aclaris’ current beliefs and expectations. These forward-looking statements include expectations regarding its plans for its development programs, including its plans to seek a development and commercialization partner for lepzacitinib, the clinical development of ATI-2138, its plan to support Washington University in St. Louis in its investigator-initiated Phase 1b/2 trials of zunsemetinib, the sufficiency of its cash, cash equivalents and marketable securities to fund its operations into 2028, as well as its strategic plans and strategic review. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials, Aclaris’ reliance on third parties over which it may not always have full control, Aclaris’ ability to enter into strategic partnerships on commercially reasonable terms, the uncertainty regarding the macroeconomic environment and other risks and uncertainties that are described in the Risk Factors section of Aclaris’ Annual Report on Form 10-K for the year ended December 31, 2023, and other filings Aclaris makes with the U.S. Securities and Exchange Commission from time to time. These documents are available under the “SEC Filings” page of the “Investors” section of Aclaris’ website at www.aclaristx.com. Any forward-looking statements speak only as of the date of this press release and are based on information available to Aclaris as of the date of this release, and Aclaris assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.
| Aclaris Therapeutics, Inc. Condensed Consolidated Statements of Operations (unaudited, in thousands, except share and per share data) | ||||||||||||||||
| Three Months Ended | Six Months Ended | |||||||||||||||
| June 30, | June 30, | |||||||||||||||
| 2024 | 2023 | 2024 | 2023 | |||||||||||||
| Revenues: | ||||||||||||||||
| Contract research | $ | 625 | $ | 875 | $ | 1,281 | $ | 1,764 | ||||||||
| Licensing | 2,141 | 994 | 3,882 | 2,633 | ||||||||||||
| Total revenue | 2,766 | 1,869 | 5,163 | 4,397 | ||||||||||||
| Costs and expenses: | ||||||||||||||||
| Cost of revenue (1) | 624 | 1,042 | 1,433 | 1,850 | ||||||||||||
| Research and development (1) | 8,759 | 25,275 | 18,604 | 47,862 | ||||||||||||
| General and administrative (1) | 4,752 | 8,317 | 11,596 | 17,107 | ||||||||||||
| Licensing | 1,285 | 550 | 2,316 | 1,611 | ||||||||||||
| Revaluation of contingent consideration | 200 | (1,500 | ) | 3,000 | (2,300 | ) | ||||||||||
| Total costs and expenses | 15,620 | 33,684 | 36,949 | 66,130 | ||||||||||||
| Loss from operations | (12,854 | ) | (31,815 | ) | (31,786 | ) | (61,733 | ) | ||||||||
| Other income, net | 1,868 | 2,246 | 3,859 | 4,004 | ||||||||||||
| Net loss | $ | (10,986 | ) | $ | (29,569 | ) | $ | (27,927 | ) | $ | (57,729 | ) | ||||
| Net loss per share, basic and diluted | $ | (0.15 | ) | $ | (0.42 | ) | $ | (0.39 | ) | $ | (0.84 | ) | ||||
| Weighted average common shares outstanding, basic and diluted | 71,291,400 | 70,633,528 | 71,183,129 | 68,763,542 | ||||||||||||
| (1) Amounts include stock-based compensation expense as follows: | ||||||||||||||||
| Cost of revenue | $ | 223 | $ | 473 | $ | 475 | $ | 772 | ||||||||
| Research and development | 1,097 | 3,494 | 1,068 | 6,096 | ||||||||||||
| General and administrative | 1,583 | 2,555 | 3,449 | 6,460 | ||||||||||||
| Total stock-based compensation expense | $ | 2,903 | $ | 6,522 | $ | 4,992 | $ | 13,328 | ||||||||
| Aclaris Therapeutics, Inc. Selected Consolidated Balance Sheet Data (unaudited, in thousands, except share data) | |||||||
| June 30, 2024 | December 31, 2023 | ||||||
| Cash, cash equivalents and marketable securities | $ | 149,871 | $ | 181,877 | |||
| Total assets | $ | 161,071 | $ | 197,405 | |||
| Total current liabilities | $ | 15,682 | $ | 30,952 | |||
| Total liabilities | $ | 27,249 | $ | 40,226 | |||
| Total stockholders' equity | $ | 133,822 | $ | 157,179 | |||
| Common stock outstanding | 71,332,825 | 70,894,889 | |||||
| Aclaris Therapeutics, Inc. Selected Consolidated Cash Flow Data (unaudited, in thousands) | ||||||||
| Six Months Ended June 30, 2024 | Six Months Ended June 30, 2023 | |||||||
| Net loss | $ | (27,927 | ) | $ | (57,729 | ) | ||
| Depreciation and amortization | 485 | 416 | ||||||
| Stock-based compensation expense | 4,992 | 13,328 | ||||||
| Revaluation of contingent consideration | 3,000 | (2,300 | ) | |||||
| Changes in operating assets and liabilities | (13,687 | ) | (722 | ) | ||||
| Net cash used in operating activities | $ | (33,137 | ) | $ | (47,007 | ) | ||
Aclaris Therapeutics Contact:
investors@aclaristx.com
